



Team meeting in Colorado



Autumn in Colorado



Reviewing the treatment protocol

Second U.S. MDMA-Assisted Psychotherapy for PTSD Study Site Trains a New Generation of Therapists

Our new study in Boulder, Colorado, will explore the safety and effectiveness of MDMA-assisted psychotherapy for PTSD when one member of the co-therapist team is an experienced therapist and the other an intern working under supervision for credit towards licensure. The use of interns is an effort both to reduce costs and to train the next generation of therapists trained in our treatment method.

From September 21-23, 2012, MAPS Director of Clinical Research Amy Emerson and Lead Clinical Research Associate Berra Yazar-Klosinski, Ph.D., visited the study site. They met with Principal Investigator Marcela Ot'alora, L.P.C., co-investigators, and other study staff to conduct a final training on the protocol and study documents, as well as to review our MDMA Investigator's Brochure and new safety data from completed MAPS clinical trials.

\$497,000 estimated study cost / \$372,000 still needed

Study Timeline

February 2013 (estimated): Subject screening begins
 October 25, 2012: Business license issued for study site
 September 21-23, 2012: Study initiation meeting (pictured)
 July 31, 2012: DEA requires new business license after site inspection
 May 15, 2012: DEA approves protocol

May 4, 2012: FDA approves protocol
 April 8, 2012: Therapist teams complete training
 March 9, 2012: IRB approves protocol
 December 9, 2011: Planning meeting takes place at MAPS' 25th anniversary conference



Boulder MDMA-assisted psychotherapy for PTSD study team



MAPS Lead Clinical Research Associate
Berra Yazar-Klosinski, Ph.D.



Boulder study Clinical Investigator
Marcela Ot'alora, M.A., L.P.C



MAPS Director of Clinical Research
Amy Emerson